Tilray Brands, Inc. (TLRY) Suffers a Larger Drop Than the General Market: Key Insights

Wednesday, Mar 18, 2026 7:17 pm ET2min read
TLRY--
Aime RobotAime Summary

- Tilray BrandsTLRY-- (TLRY) fell 3.17% to $6.73, underperforming broader markets like S&P 500 (-1.36%) and NasdaqNDAQ-- (-1.46%).

- The stock dropped 7.46% monthly, lagging medical sector861075-- (-5.66%), with Q2 EPS forecast at -$0.14 (86% improvement YoY) and $205.93M revenue (+10.85% YoY).

- TLRYTLRY-- holds Zacks Rank #3 (Hold) despite 2024 guidance showing -$0.56 EPS (-660% YoY) and $872M revenue (+6.17% YoY), while its industry ranks 156th (bottom 37%).

In the latest trading session, Tilray BrandsTLRY--, Inc. (TLRY) closed at $6.73, marking a -3.17% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 1.36%. Elsewhere, the Dow saw a downswing of 1.64%, while the tech-heavy Nasdaq depreciated by 1.46%.

Shares of the company have depreciated by 7.46% over the course of the past month, underperforming the Medical sector's loss of 5.66%, and the S&P 500's loss of 1.76%.

Analysts and investors alike will be keeping a close eye on the performance of Tilray Brands, Inc. in its upcoming earnings disclosure. The company's upcoming EPS is projected at -$0.14, signifying a 86.00% increase compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $205.93 million, indicating a 10.85% increase compared to the same quarter of the previous year.

For the full year, the Zacks Consensus Estimates project earnings of -$0.56 per share and a revenue of $871.99 million, demonstrating changes of -660% and +6.17%, respectively, from the preceding year.

It's also important for investors to be aware of any recent modifications to analyst estimates for Tilray Brands, Inc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.

Based on our research, we believe these estimate revisions are directly related to near-term stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Right now, Tilray Brands, Inc. possesses a Zacks Rank of #3 (Hold).

The Medical - Products industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 156, placing it within the bottom 37% of over 250 industries.

The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow TLRYTLRY-- in the coming trading sessions, be sure to utilize Zacks.com.

Free Report: Profiting from the 2nd Wave of AI Explosion

The next phase of the AI explosion is poised to create significant wealth for investors, especially those who get in early. It will add literally trillion of dollars to the economy and revolutionize nearly every part of our lives.

Investors who bought shares like Nvidia at the right time have had a shot at huge gains.

But the rocket ride in the "first wave" of AI stocks may soon come to an end. The sharp upward trajectory of these stocks will begin to level off, leaving exponential growth to a new wave of cutting-edge companies.

Zacks' AI Boom 2.0: The Second Wave report reveals 4 under-the-radar companies that may soon be shining stars of AI’s next leap forward.

Access AI Boom 2.0 now, absolutely free >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report



Tilray Brands, Inc. (TLRY): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Zacks is the leading investment research firm focusing on equities earnings estimates and stock analysis for the individual investor, including stock picks, stock screening, portfolio stock tracker and stock screeners. Copyright 2006-2026 Zacks Equity Research, Inc. editor@zacks.com (Manaing editor) webmaster@zacks.com (Webmaster)

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet